Most comparisons in this field ask whether a drug beats lifestyle change. This one asked a more useful question: whether the same drug does better with structured support attached[1]. Across 42 randomized trials in adolescents aged 10 to 19, the answer was yes every time. The adult version of the ranking is in what a GLP-1 actually costs.
All pharmacological treatments — GLP-1 drugs, metformin, orlistat and phentermine-topiramate — produced significantly greater BMI reductions when paired with health behavior and lifestyle treatment than when given alone. Not marginally, and not for one drug: the pattern held across the board.
Lifestyle treatment alone was not trivial either. On its own it reduced BMI by 3.85 points (95% CI -4.91 to -2.80) and BMI z score by 0.89, which the authors describe as making it an indispensable component rather than a formality to be waived once a prescription exists.
For anyone buying, that is the line worth carrying away, and it has an uncomfortable implication for how these drugs are actually sold. A service that ships a vial with an intake form and no structured behavioral support is delivering the arm of this comparison that performed worse — consistently, across every drug tested. Patients describe that variation themselves in what patients said when asked, where support ranged from thorough to nearly absent.
Two boundaries limit how far this travels. The participants were adolescents with a median age of 14.5, and BMI z score is an age-and-sex-standardized measure that does not convert into an adult figure. And follow-up was typically six to twelve months, which the authors call short-term — so this describes getting weight off rather than keeping it off, a distinction that matters given the figures in two thirds stop within a year and the two regain numbers.